Mesothelioma Cancer: An Overview
Mesothelioma, specifically malignant mesothelioma, is a rare but aggressive form of cancer that originates in the mesothelium. The mesothelium is a thin, protective layer of tissue that lines the body’s internal cavities and covers most of the internal organs. This thin membrane is essential for allowing the internal organs, such as the lungs, heart, and digestive organs, to move smoothly against each other. When cancerous, the disease often presents not as a single, isolated tumor mass, but as a thickening or blanket of tumors that spreads along these lining surfaces, which complicates treatment significantly.
Unlike many other cancers, mesothelioma’s development is strongly linked to a single primary cause, which is exposure to asbestos. Due to the disease’s long latency period—often 20 to 40 years between the initial exposure and the appearance of symptoms—diagnosis typically occurs in later stages when the cancer is advanced. The prognosis for this aggressive disease is generally poor, with the average life expectancy for many patients being around 12 months after diagnosis, though outcomes vary based on the cancer’s location, cell type, and the aggressiveness of the treatment plan adopted.
Etiology and Major Risk Factors
The single most critical and overwhelmingly common cause of mesothelioma is the inhalation or ingestion of asbestos fibers. Asbestos is a naturally occurring silicate mineral prized historically for its resistance to heat and fire, leading to its widespread use in construction, shipbuilding, automotive repair, and various industrial and military applications before its risks became fully understood.
When disturbed, asbestos-containing materials release microscopic, needle-like fibers into the air. Once these fibers are inhaled, they can become permanently lodged in the pleural or peritoneal tissue. This presence leads to chronic inflammation, disruption of cellular processes like mitosis, and the generation of free radicals, which ultimately cause genetic changes and the development of cancer cells in the mesothelium. Occupations with the highest risk include military service, shipbuilding, mining, construction, and auto repair.
While asbestos is the primary culprit, other factors contribute to risk. These include exposure to the asbestos-like mineral erionite, which was once used in road construction, and exposure to high doses of radiation from past cancer treatments, particularly to the chest. Furthermore, a genetic predisposition, specifically an inherited change in the BAP1 gene, has been identified as a factor that can increase a person’s susceptibility to mesothelioma and other cancers. Interestingly, while smoking is a major risk factor for other lung diseases, it is not directly linked to mesothelioma itself, though smoking combined with asbestos exposure significantly elevates the risk of lung cancer.
Classification of Mesothelioma by Location and Cell Type
Mesothelioma is categorized based on the site of its origin and the cellular characteristics of the tumor.
The most common form is Pleural Mesothelioma, which accounts for approximately 70% to 79% of all cases. This type develops in the pleura, the thin lining around the lungs and inside the chest cavity. The symptoms are often respiratory in nature due to the cancer’s physical presence and its tendency to cause fluid buildup, known as pleural effusion.
The second most common type is Peritoneal Mesothelioma, which occurs in the peritoneum, the lining of the abdominal cavity. This form accounts for less than 20% of cases and often presents with gastrointestinal or abdominal symptoms, sometimes leading to misdiagnosis as common digestive conditions like colitis.
The remaining types, Pericardial Mesothelioma (affecting the heart lining, or pericardium) and Mesothelioma of the Tunica Vaginalis (affecting the lining around the testicles), are extremely rare, each accounting for about 1% or less of all diagnoses. Treatment for pericardial mesothelioma is particularly challenging due to its proximity to the heart, while testicular mesothelioma generally has a better prognosis than the pleural type.
Mesothelioma tumors are also classified by cell type: Epithelioid, Sarcomatoid, and Biphasic. Epithelioid cells are the most common and are associated with the best prognosis. Sarcomatoid cells are less common, but they are more aggressive, grow and spread rapidly, and are the most resistant to conventional treatments. Biphasic tumors contain a mixture of both epithelioid and sarcomatoid cells.
Signs and Symptoms Dependent on Location
The signs and symptoms of mesothelioma are often non-specific and depend heavily on where the cancer is located, which can make early diagnosis difficult.
Patients with Pleural Mesothelioma typically experience symptoms related to the chest and breathing. Common indicators include persistent shortness of breath (dyspnea), a painful or dry cough, and pain in the chest or under the rib cage. As the disease advances, symptoms can also include difficulty swallowing, a feeling of extreme tiredness or fatigue, and unexplained weight loss.
For Peritoneal Mesothelioma, the symptoms are centered on the abdomen. These include abdominal pain, swelling, or tenderness, often due to the accumulation of fluid (ascites). Other signs are changes in bowel habits, such as constipation or diarrhea, and the general cancer symptoms of unexplained weight loss, nausea, and fatigue.
Treatment and Management Strategies
Due to the aggressive and often widespread nature of the cancer, there is typically no single cure for mesothelioma. Management relies on a multimodal treatment approach, which combines two or more therapeutic strategies tailored to the cancer’s stage, location, and cell type. Palliative care is also a crucial aspect of treatment, helping patients manage symptoms and side effects to maintain quality of life.
Surgical options aim to remove as much cancerous tissue as possible. Procedures for pleural mesothelioma include the radical Extrapleural Pneumonectomy (EPP), which removes the affected lung, pleura, diaphragm, and part of the pericardium, and the less invasive, lung-sparing Pleurectomy with Decortication (P/D). For peritoneal mesothelioma, cytoreduction surgery combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), where heated chemotherapy drugs are circulated directly in the abdomen, has shown promising results in improving survival rates.
Systemic therapies include Chemotherapy, which uses drugs to target and destroy fast-growing cancer cells, and Immunotherapy, which trains the body’s own immune system to identify and fight the cancer. Combination immune checkpoint inhibitors, such as nivolumab and ipilimumab, are increasingly being used for unresectable cases. Radiation Therapy uses high-energy X-rays to destroy cancer cells, often used adjunctively after surgery or palliatively to relieve symptoms like pain or difficulty breathing.
Emerging and investigational treatments, such as Tumor Treating Fields (TTFields) and Targeted Therapies that focus on specific genetic changes like BAP1 mutations, are continuously being explored in clinical trials, offering hope for improved prognoses in the future. Since avoiding asbestos exposure is the only known way to significantly reduce the risk of developing this deadly disease, prevention through awareness and strict environmental control remains paramount.